Pharmacokinetic evaluation of linezolid in patients with major thermal injuries.;Pharmacocinétique du linézolide chez des patients souffrant de brûlures sévères

Pathologie Biologie

Volumn 58, Issue 2, 2010, Pages

  Le Floch, R ^a   Arnould, J F ^a   Vinsonneau, C ^b   Hovsepian, L ^c   Stephanazzi, J ^b   Bret, P ^d   Birraux, G ^d   Lovering, A M ^e  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Institut Cochin   (France)

^c SGS   (France)

^d PFIZER INC   (United States)

^e NORTH BRISTOL NHS TRUST   (United Kingdom)

Author keywords

Burns; Comparison; Healthy volunteers; Linezolid; Pharmacokinetics

Indexed keywords

LINEZOLID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BURN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; STEADY STATE; THERMAL INJURY;

ACETAMIDES; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BURNS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OXAZOLIDINONES; YOUNG ADULT;

EID: 77952099054     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2009.07.025     Document Type: Article

References (25)

1. Weinbren M.J. Pharmacokinetics of antibiotics in burns patients. J Antimicrob Chemother 1999, 44:319-327.
2. Bergman S.J., Speil C., Short M., Koirala J. Pharmacokinetic and pharmacodynamic aspects of antibiotic use in high-risk populations. Infect Dis Clin North Am 2007, 21:821-846.
3. Boucher B.A., Kuhl A.M., Hickerson D.A. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin Infect Dis 1992, 14:458-463.
4. Le Floch R, Arnould JF, Pilorget A, Naux E. Dosages d'antibiotiques. Que peut-on en tirer? Société française d'études et de traitement des brûlures XXVIIe Congrès, 2007, CL10.
5. Demling R.H., Waterhouse B. The increasing problem of wound bacterial burden and infection in acute and chronic soft-tissue wounds caused by methicillin-resistant Staphylococcus aureus. J Burns Wounds 2007, 7:e8.
6. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 23:2138-2144.
7. Lodise T.P., Lomaestro B., Graves J., Drusano G.L. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008, 52:1330-1336.
8. Vardakas K.Z., Ntziora F., Falagas M.E. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother 2007, 8:2381-2400.
9. Broder K.W., Moise P.A., Schlutz R.O., Forrest A., Schentag J.J. Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissues and postoperative osteomyelitis. Ann Plast Surg 2004, 52:385-390.
10. Atkins J.L., Hidvegi N., Teare L., Dziewulski P. The use of linezolid in the treatment of vancomycin-resistant enterococcal septicaemia in two patients with burn injuries. Burns 2002, 28:185-188.
11. Ackerman B.H., Reilly K.J., Guiday R.E., Patton M.L., Haith L.R. Quality assurance assessment of the use of linezolid in the treatment of thermal injury patients at a community teaching hospital. J Burn Care Res 2007, 28:145-151.
12. Jungbluth G.L., Welhman I.R., Hopkins N.K. Linezolid pharmacokinetics in paediatric patients: an overview. Pediatr Infect Dis J 2003, 22:S153-S157.
13. Bosso J.A., Flume P.A., Gray S.L. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2004, 48:281-284.
14. Mansour E., Jacob E., Monchi E., Ledoux D., Canivet J.L., De Mol P., et al. Occurrence of MRSA endocarditis during linezolid treatment. Eur J Clin Microbiol Infect Dis 2003, 22:372-373.
15. Tobin C.M., Sunderland J., White L.O., MacGowan A.P. A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum. J Antimicrob Chemother 2001, 48:605-608.
16. Stalker D.J., Jungbluth G.L., Hopkins N.K., Batts D.H. Pharmacokinetics and tolerance of single- and multiple-dose of intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003, 51:1239-1246.
17. Meagher A.K., Forrest A., Rayner C.R., Birmingham M.C., Schentag J.J. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003, 47:548-553.
18. Mohr J.F., Ostrosky - Zeichner L., Wainright C.R., Parks D.H., Hollenbeck T.C., Ericsson C.D. Pharmacokinetic evaluation of a single-dose intravenous daptomycin in patients with thermal injury. Antimicrob Agents Chemother 2008, 52:1891-1893.
19. Rayner C.R., Forrest A., Meagher A.K., Birmingham M.C., Schentag J.J. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate-use program. Clin pharmacokinet 2003, 42:1411-1423.
20. Kuti J.L., Kiffer C.R., Mendes C.M., Nicolau D.P. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase - negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect 2008, 14:116-123.
21. Moise P.A., Castro R.S., Sul C., Forrest A., Sakoulas G. Relationship of linezolid minimum inhibitory concentration and time to bacterial eradication in treatment for methicillin resistant Staphylococcus aureus infection. Ann Pharmacother 2008, 42:592-593.
22. Adembri C., Fallani S., Cassetta M.I., Arrigucci S., Ottaviano A., Pecile P., et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill patients: Intermittent versus continuous infusion. Int J Antimicrob Agents 2008, 31:122-129.
23. Jacqueline C., Batart E., Perez L., Boutoille D., Hamel A., Caillon J., et al. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in methicillin resistant Staphylococcus aureus rabbit endocarditis model. Antmicrob Agents Chemother 2002, 46:3706-3711.
24. Raineri S.M., Stabile A., Giarratano A. Linezolid bolus VS linezolid in continuous infusion - the host response in patients with severe sepsis. Revista de Ciencias de Saude de Mecau 2005, 5:87-91.
25. Boak L.M., Li J., Rayner C.J., Nation R.L. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother 2007, 51:1287-1292.